Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

NewAmsterdam Pharma Company NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NAMSW
DateTimeSourceHeadlineSymbolCompany
06/11/20248:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
06/11/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark OfficeNASDAQ:NAMSWNewAmsterdam Pharma Company NV
06/07/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
06/07/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/29/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneNASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/21/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/09/20244:18PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/09/20244:15PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/09/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/09/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/08/20244:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/03/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
05/02/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
04/09/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSWNewAmsterdam Pharma Company NV
04/01/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
03/25/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSWNewAmsterdam Pharma Company NV
03/12/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSWNewAmsterdam Pharma Company NV
02/28/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSWNewAmsterdam Pharma Company NV
02/26/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSWNewAmsterdam Pharma Company NV
02/13/202410:40PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
02/13/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
02/01/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/08/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
01/04/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces 2024 Strategic PrioritiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/13/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
10/23/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/21/20237:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/20/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
08/14/20234:01PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
08/07/20237:15AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
 Showing the most relevant articles for your search:NASDAQ:NAMSW